|
US8258163B2
(en)
|
2008-06-04 |
2012-09-04 |
Board Of Regents, The University Of Texas System |
Small-molecule agonists for type-2 orexin receptor
|
|
EP2694472B1
(en)
|
2011-04-05 |
2020-03-11 |
Takeda Pharmaceutical Company Limited |
Sulfonamide derivative and use thereof
|
|
US10017481B2
(en)
|
2012-03-17 |
2018-07-10 |
Polyphor Ag |
Conformationally constrained, fully synthetic macrocyclic compounds
|
|
WO2014198880A1
(en)
|
2013-06-14 |
2014-12-18 |
Ferrer Internacional, S.A. |
2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
|
|
US20160250224A1
(en)
|
2013-09-24 |
2016-09-01 |
The Board Of Regents Of The University Of Texas System |
Orexin-control of bone formation and loss
|
|
CA2930693A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior Unversity |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
PE20161064A1
(es)
|
2013-12-12 |
2016-10-28 |
Univ Tsukuba |
Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
|
|
WO2015147240A1
(ja)
|
2014-03-28 |
2015-10-01 |
国立大学法人筑波大学 |
敗血症の予防治療剤
|
|
KR102455043B1
(ko)
|
2014-09-11 |
2022-10-13 |
얀센 파마슈티카 엔.브이. |
치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
|
|
WO2016133160A1
(ja)
|
2015-02-19 |
2016-08-25 |
国立大学法人筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
WO2016199906A1
(ja)
|
2015-06-12 |
2016-12-15 |
国立大学法人筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
PL3411358T3
(pl)
|
2016-02-04 |
2022-02-28 |
Takeda Pharmaceutical Company Limited |
Podstawiony związek piperydynowy i jego zastosowanie
|
|
WO2018164191A1
(ja)
|
2017-03-08 |
2018-09-13 |
武田薬品工業株式会社 |
置換ピロリジン化合物およびその用途
|
|
US11034700B2
(en)
|
2017-03-08 |
2021-06-15 |
Takeda Pharmaceutical Company Limited |
Substituted pyrrolidine compound and use thereof
|
|
US20200207734A1
(en)
|
2017-08-03 |
2020-07-02 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
US11319286B2
(en)
|
2017-08-03 |
2022-05-03 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
CN111132975B
(zh)
|
2017-09-28 |
2023-05-23 |
勃林格殷格翰国际有限公司 |
N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
|
|
WO2019117148A1
(ja)
|
2017-12-12 |
2019-06-20 |
国立大学法人 筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
MX2020010155A
(es)
|
2018-03-27 |
2021-03-25 |
Univ Texas |
Compuestos de ox2r.
|
|
JP7413261B2
(ja)
|
2018-06-29 |
2024-01-15 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
US12077522B2
(en)
|
2018-06-29 |
2024-09-03 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
EP3896060B1
(en)
|
2018-12-12 |
2023-08-16 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
JP7379374B2
(ja)
|
2018-12-12 |
2023-11-14 |
武田薬品工業株式会社 |
複素環化合物
|
|
SG11202106791XA
(en)
|
2019-01-31 |
2021-07-29 |
Takeda Pharmaceuticals Co |
Heterocyclic compound and use thereof
|
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
|
WO2020167701A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Pyrrolidine orexin receptor agonists
|
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
BR112022004576A2
(pt)
|
2019-09-13 |
2022-06-14 |
Takeda Pharmaceuticals Co |
Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
|
|
FI4065585T3
(fi)
*
|
2019-11-25 |
2025-09-26 |
Alkermes Inc |
Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
|
|
WO2021106975A1
(ja)
|
2019-11-27 |
2021-06-03 |
武田薬品工業株式会社 |
複素環化合物
|
|
US11352357B2
(en)
|
2019-11-27 |
2022-06-07 |
Sumitomo Dainippon Pharma Co., Ltd. |
Cycloalkylurea derivative
|
|
MX2022008392A
(es)
|
2020-01-10 |
2022-08-08 |
Takeda Pharmaceuticals Co |
Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
|
|
KR20230040953A
(ko)
|
2020-07-17 |
2023-03-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
치환된 피페리딘 화합물 및 이의 적용례
|
|
BR112023002957A2
(pt)
|
2020-08-18 |
2023-04-04 |
Merck Sharp & Dohme Llc |
Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
|
|
EP4199925A4
(en)
|
2020-08-18 |
2024-08-28 |
Merck Sharp & Dohme LLC |
CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
|
|
US12503475B2
(en)
|
2020-09-03 |
2025-12-23 |
Centessa Pharmaceuticals (Uk) Limited |
Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
|
|
WO2022051583A1
(en)
|
2020-09-03 |
2022-03-10 |
Orexia Therapeutics Limited |
Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
|
|
JP2022064180A
(ja)
|
2020-10-13 |
2022-04-25 |
武田薬品工業株式会社 |
複素環化合物
|
|
EP4236938A4
(en)
|
2020-11-02 |
2024-10-16 |
Merck Sharp & Dohme LLC |
MACROCYCLIC UREA-OREX RECEPTOR AGONISTS
|
|
WO2022109117A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
|
|
EP4255429A4
(en)
|
2020-12-03 |
2024-12-11 |
Merck Sharp & Dohme LLC |
3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
US20240101555A1
(en)
|
2020-12-16 |
2024-03-28 |
Merck Sharp & Dohme Llc |
Urea orexin receptor agonists
|
|
US12006330B2
(en)
*
|
2020-12-21 |
2024-06-11 |
Alkermes, Inc. |
Substituted macrocyclic compounds and related methods of treatment
|
|
US20240174605A1
(en)
|
2021-03-03 |
2024-05-30 |
Research Triangle Institute |
Arylsulfonamides as orexin receptor agonists
|
|
WO2022207935A1
(en)
|
2021-04-02 |
2022-10-06 |
Orexia Therapeutics Limited |
2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
|
|
KR20240004802A
(ko)
|
2021-05-03 |
2024-01-11 |
재즈 파마슈티칼즈 아일랜드 리미티드 |
오렉신 수용체 효능제 및 그의 용도
|
|
CA3219888A1
(en)
|
2021-05-26 |
2022-12-01 |
Masafumi KOMIYA |
Phenyl urea derivative
|
|
EP4359387A1
(en)
|
2021-06-25 |
2024-05-01 |
Jazz Pharmaceuticals Ireland Limited |
Sulfonamide orexin receptor agonists and uses thereof
|
|
WO2023017180A1
(en)
|
2021-08-13 |
2023-02-16 |
Orexia Therapeutics Limited |
Peptide derivatives and related uses as orexin agonists
|